HomeAXGN • NASDAQ
AxoGen, Inc Common Stock
$17.81
0.00%
0.00 Today
Pre-market:
$17.55
(1.46%)-0.26
Closed: Apr 2, 8:47:05 AM GMT-4 · USD · NASDAQ · Disclaimer
Market news
Financials
Income Statement
020M40M
Revenue
Net Income
Revenue
Net income
(USD)Dec 2024Y/Y change
Revenue
49.41M15.10%
Operating expense
35.56M0.97%
Net income
450.00K111.56%
Net profit margin
0.91110.03%
Earnings per share
0.07216.67%
EBITDA
3.72M335.76%
Effective tax rate
050M100M150M200M
Total Assets
Total Liabilities
Total assets
Total liabilities
(USD)Dec 2024Y/Y change
Cash and short-term investments
33.48M7.92%
Total assets
203.73M3.51%
Total liabilities
99.82M-1.33%
Total equity
103.91M
Shares outstanding
44.34M
Price to book
7.58
Return on assets
2.55%
Return on capital
2.92%
-10M0
Net Change in Cash
Net change in cash
(USD)Dec 2024Y/Y change
Net income
450.00K111.56%
Cash from operations
8.74M4,239.81%
Cash from investing
-813.00K-193.50%
Cash from financing
970.00K132.06%
Net change in cash
8.89M12,802.86%
Free cash flow
7.99M2,626.85%
StockUS listed securityUS headquartered
Previous close
$17.81
Year range
$5.55 - $21.00
Market cap
789.76M USD
Avg Volume
644.82K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator. As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Founded
2002
Employees
452
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Main menu
Google apps